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Background/Objectives 
The association of weight changes with cardiometabolic biomarkers in South Asians has been 
sparsely studied.  
Subjects/Methods 
We measured cardiometabolic biomarkers at baseline and after 3 years in the Prevention of 
Diabetes and Obesity in South Asians (PODOSA) Trial. We investigated the effect of a 
lifestyle intervention on biomarkers in the randomised groups. In addition, treating the 
population as a single cohort, we estimated the association between change in weight and 
change in biomarkers. 
Results 
Complete data were available at baseline and 3 years in 151 participants. At 3 years there was 
an adjusted mean reduction of 1·44kg (95% CI 0.18 to 2.71) in weight and 1.59cm (95% CI 
0.08 to 3.09) in waist circumference in the intervention, compared with control, arm. There 
was no clear evidence of difference between intervention and control arms in change of mean 
value of any biomarker. As a single cohort, every 1kg weight reduction during follow-up was 
associated with a reduction in triglycerides (-1.3%, p=0.048), ALT (-2.5%, p=0.032), GGT (-
2.2%, p=0.040), leptin (-6.5%, p<0.0001), insulin (-3.7% p<0.001), fasting glucose (-0.8%, 
p<0.001), 2-hour glucose (-2.3%, p<0.001) and HOMA-IR (-4.5%, p<0.001).There was no 
evidence of associations with other lipid measures, t-PA, markers of inflammation, or blood 
pressure.  
Conclusions 
We demonstrate that modest weight decrease in SAs is associated with improvements in 
markers of total and ectopic fat as well as insulin resistance and glycaemia in South Asians at 
risk of diabetes.  Future trials with more intensive weight change are needed to extend these 
findings.   
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INTRODUCTION 
People of South Asian ethnic origin are at increased risk of type 2 diabetes over the full range 
of body mass indices (BMI), and when living in high-income countries such as the UK, are at 
higher risk compared to those of White European origin 1. As such, existing clinical 
guidelines for the prevention of diabetes have emphasised the importance of targeting lower 
BMI in this group to mitigate this elevated risk 2,3. However, clinical trials involving lifestyle 
interventions have generally only had very modest effects in reducing adiposity among South 
Asians 4. For example, although incident diabetes was reduced by lifestyle intervention in the 
Indian Diabetes Prevention Programme (IDPP-1), absolute BMI and waist circumference 
increased in all trial arms over 30 months of follow-up 5. The Prevention of Diabetes and 
Obesity in South Asians (PODOSA) study of 171 South Asians with impaired glucose 
tolerance or impaired fasting glucose recently reported that the group who received a 
culturally adapted lifestyle intervention lost an adjusted mean difference of 1.64kg (95% CI 
0.44 to 2.83) in weight and 1.89cm (95% CI 0.52 to 3.27) in waist circumference, compared 
to the control group 6,7.  
 
It is not known whether a lifestyle intervention resulting in a weight loss of this magnitude 
will be associated with appreciable changes to metabolic and cardiovascular risk in South 
Asians. This question is important given the considerable investment of resources required to 
achieve modest changes in adiposity. The Practice-based Opportunities for Weight Reduction 
University of Pennsylvania (POWER-UP) trial recently showed that an enhanced intervention 
that results in a mean 2.9kg weight loss compared to the control arm over 2 years resulted in 
only small changes in insulin, HOMA and triglycerides 8.  A recent meta-analysis of lifestyle 
interventions in people with type 2 diabetes found that small reductions in BMI (standardised 
difference in mean BMI 0.29; 95% CI 0.06 to 0.52) resulted in small reductions in blood 
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pressure and improved glycaemic control, but no change in lipids 9.  Trials of weight loss 
interventions have also been performed in people without type 2 diabetes in a range of 
settings 9. However, such studies typically have included only small numbers of South 
Asians. Given the elevated cardiometabolic risks among South Asians, it is important to 
investigate the effect of lifestyle intervention and associated modest weight loss specifically 
in this ethnic group. 
 
The aim of the present study was to utilise data from the PODOSA Trial in a planned 
exploratory analyses to explore the effect of weight loss on the cardiometabolic risk profile 
over four domains (i.e. lipids, liver function, inflammatory, and metabolic) to address two 
pre-specified research questions.  The first was to determine the effects of the culturally-
adapted PODOSA lifestyle intervention 10 on cardiometabolic risk factors using an intention-
to-treat analysis.  In the second pre-specified analysis, we wished to explore the association 
of changes in weight and waist circumference with these risk factors using data for all 
individuals in this trial (i.e. combining intervention and control groups) as a single cohort 
study.  
 
SUBJECTS AND METHODS 
Trial design and participants 
PODOSA was a non-blinded, family clustered, randomised controlled trial conducted in 
Scottish communities, the details of which have been described previously 6,7,11. In brief, 
recruitment for screening used a multi-pronged approach (i.e. via the NHS and directly from 
the community) and took place between 2007 and 2009. Men and women of Pakistani or 
Indian ethnic origin aged 35 years or older were eligible for screening if their waist size was 
greater than 90cm and 80cm in men and women, respectively; the screened individual had to 
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be free of a diagnosis of diabetes; and the family cook was to be willing to cooperate with the 
trial. Final enrolment was based on confirmed impaired glucose tolerance or impaired fasting 
glucose based on World Health Organization (WHO) criteria during the screening visit 12. 
Families living in the same household, or close to the index participant, aged 18 or over, were 
randomised to intervention or control arms of the trial as a cluster. Those randomised to 
intervention were offered information and demonstrations on healthy shopping and cooking 
practices, and received 15 visits from a dietitian over 3 years of follow-up, who advised on 
achieving weight loss through calorie deficit and physical activity of at least 30 minutes per 
day using culturally sensitive techniques. The control group was given standardised written 
and verbal advice on healthy eating, diabetes prevention, promotion of physical activity, and 
on accessing other weight control and physical activity services over four visits (baseline, 
then annually) with a dietitian. In total, 78 families were randomised to each of the 
intervention and control arms, with 85 and 86 pre-diabetes individuals randomised, 
respectively. 
 
For all participants, at the baseline and 3-year visits (among others) trained dietitians 
collected anthropometric data (weight [to the nearest 0.1kg] and height, hip and waist 
circumferences [to the nearest cm]), blood pressure measurements, and overnight fasted 
venous blood samples following standard operating procedures for the trial 7. Weight was 
measured using SECA 862 digital scales which were calibrated annually. Two unblinded 
blood pressure measures (Omron M6 BP monitor, calibrated anually) were taken at each visit 
by study dietitians, and if >10mmHg between either systolic or diastolic then a 3rd measure 
was performed. The only blinding of group status was at the final measure of weight and 
waist size, which was performed by independent research nurses. Treatment with medications 
was based on self-reported (yes/no) responses to questions as to whether participants were 
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taking statins or anti-hypertensives at baseline and the final visit; data on drug and dose are 
not available. 
 
Ethical approval 
Individual participants gave written informed consent and ethical approval was granted by the 
Scotland A Multi-Centre Research Ethics Committee. 
 
Biochemical measurements 
Biochemical measurements were made by technicians blinded to intervention status at both 
time points. Measures of high sensitivity C-reactive protein (CRP), total cholesterol, high 
density lipoprotein (HDL)-cholesterol, triglycerides, gamma-glutamyl transferase (GGT), 
aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were performed on an 
automated clinically validated platform (Roche c311, Roche Diagnostics, Burgess Hill, UK). 
LDL cholesterol was calculated from the Friedwald equation (LDL Cholesterol = Total 
Cholesterol - HDL Cholesterol - (Triglycerides / 5)). All automated assays were performed 
using the manufacturer’s calibrators and quality control materials.  Between run coefficients 
of variation (CVs) were 6.4% for CRP and <1% for all other assays. Insulin (Ultrasensitive 
Mercodia ELISA, Diagenics, Milton Keynes, UK), IL-6 and leptin (R&D Systems, Oxon, 
UK) and tissue plasminogen activator (tPA) antigen (Tcoag TriniLIZE tPA, Stago, Berkshire, 
UK) were measured by commercially available ELISAs. Intra- and inter-assay CVs for the 
ELISAs were 4.8% and 6.7% for insulin; 3.9% and 12.6% for IL-6; 7.5% and 6.8% for leptin; 
and 9.4% and 6.4% for tPA. HOMA-IR was calculated: HOMA-IR = fasting plasma glucose 
(mmol/l) * fasting serum insulin (µU/l) / 22.5 13. 
 
Statistical analysis 
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Analyses were restricted to participants with complete data for all characteristics under study 
at both baseline and 3 year follow-up. The distributions of each continuous characteristic 
were examined by randomised group at baseline and 3 years and these were summarised as 
means (standard deviation [SD]) when normally distributed and median (interquartile range 
[IQR]) when skewed. Categorical variables were reported as frequencies (percentages). 
Absolute changes from baseline to 3 year follow up were calculated for weight, waist 
circumference and all biomarkers. Correlations of weight and waist circumference with other 
baseline biomarkers were tested using linear regression to confirm internal validity of the 
data. 
 
The impacts of the intervention on biomarkers were explored by linear regression. The effect 
of the intervention on each variable was estimated by comparing the mean change from 
baseline in the intervention group with the corresponding mean change in the control group; 
this approach adjusted for baseline imbalances between arms. Variables for which the 
underlying distributions were skewed were transformed to a logarithmic scale before 
conducting any formal analysis. The results are presented as relative changes (with 
corresponding 95% CIs), either by exponentiation of the parameter estimates when data were 
analysed on a logarithmic scale or by expressing the estimated effect sizes as a percent of the 
overall mean baseline value for variables which were not transformed. The linearity and 
constant variance assumptions were checked by examining plots of residuals against fitted 
values. 
 
We also investigated the effect of adiposity change on biomarkers using linear regression, 
utilising the whole cohort as a prospective cohort study regardless of intervention. Change in 
weight (per 1kg) and change in waist circumference (per 1cm) were modelled as explanatory 
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variables for changes in biomarkers. As above, skewed data were transformed to a 
logarithmic scale prior to analysis, and all estimates of effect size are expressed as percent 
change in the biomarker per 1kg change in weight or per 1cm change in waist circumference. 
We did not adjust for any factors in these analyses; randomised intervention is an effect 
mediator rather than a confounder, and demographic variables (age, sex, and ethnicity) are 
unlikely to be associated with both change in adiposity and change in biomarkers and hence 
meet the definition of confounders. 
 
The trial met with limited success in recruiting family clusters 7; in estimating the intra-class 
correlation coefficient (ICC) to account for clustering the relevant variance component was 
negative, so by convention, the estimated intra-class correlation was taken to be zero, and no 
adjustment for clustering was needed. The interpretation of the results requires context-
dependant interpretation of the number of tests done, and acknowledgment of the possibility 
of chance findings rather than formal correction for multiple comparisons 14. As such our pre-
specified analyses were conducted and although not all models are presented here (such as 
scatter plots of distributions and linear regression models of baseline data), the data presented 
are consistent with those obtained in all analyses. 
 
All data were analysed using SAS V 9.3 (SAS Institute Inc, Cary, North Carolina, USA). 
 
RESULTS 
Baseline characteristics 
There were complete data available for 151 of the 171 randomised participants (88.3%) (Fig 
1). Those with complete data had similar demographic characteristics compared to the 
complete trial group in terms of  sex (44% vs. 46% men), age (mean 53 years vs. 52 years), 
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ethnicity (Indian 33% vs. 33%), weight (mean 103kg vs. 103kg), and randomised group 
(intervention 50% vs. 50%). Characteristics of the study by randomised group at baseline are 
described in Table 1. The demographic and anthropometric characteristics of the two groups 
were very similar, although the CRP, IL-6, insulin, HOMA-IR and triglyceride levels were 
slightly higher in the control group.   
 
Correlations and associations at baseline 
Baseline correlates of both weight and waist circumference (r>0.20) included HDL-
cholesterol (inverse), CRP, leptin, insulin, HOMA-IR and diastolic blood pressure (all 
positive) (Supplemental Table S1).  
 
Effect of intervention on biomarkers 
Among those with complete data, mean weight loss in the intervention group was 1.14 kg, 
compared with a mean weight gain of 0.30 kg in the controls, an adjusted mean loss of 1.44 
kg (95% CI 0.18 to 2.71) in the intervention group. Mean waist circumference reduction in 
the intervention group was 2.22cm, compared with a reduction of 0.63cm in the controls, an 
adjusted mean reduction of 1.59cm (0.08 to 3.09) in the intervention group. This translated 
into a 1.8% (95% CI 0.2 to 3.4) lower weight and a 1.5% (95% CI 0.1 to 3.0) lower waist 
circumference in the intervention group at follow-up (Table 2). 
 
There was no evidence that the intervention had a significant effect on any mean values of the 
biomarkers of cardiometabolic risk (Table 2). 
 
Effect of weight and waist circumference change on biomarkers using data from the entire 
cohort 
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In a linear regression model each 1kg weight reduction was associated with statistically 
significant relative changes in triglycerides (-1.3%, p=0.048) ALT (-2.5%, p=0.032), GGT (-
2.2%, p=0.040), leptin (-6.5%, p<0.0001) insulin (-3.7% p=0.0005), fasting glucose (-0.8%, 
p=0.0071), 2-hour glucose (-2.3%, p=0.0002) HOMA-IR (-4.5%, p=0.0002) and absolute 
changes in these markers were commensurate (Table 3). The equivalent relative changes for 
1cm smaller waist circumference were triglycerides (-1.1%, p=0.048) ALT (-2.2%, p=0.029), 
GGT (-1.2%, p=0.196), leptin (-4.0%, p=0.0005) insulin (-2.4% p=0.0105), fasting glucose (-
0.6%, p=0.0217), 2-hour glucose (-1.7%, p=0.0010) HOMA-IR (-2.9%, p=0.0045) (Table 4). 
There was no evidence of an association of change in weight or waist circumference with t-
PA, markers of inflammation (CRP and IL-6), or blood pressure (Table 3 and 4).    
 
CONCLUSIONS 
This study makes important observations regarding the effect of modest changes in adiposity 
on biomarkers of cardiometabolic risk in South Asians. Firstly, although the intervention 
resulted in an adjusted mean loss of 1.44kg and 1.59cm in waist circumference compared to 
controls over 3 years, in our RCT based analysis this did not lead to a change in biomarkers. 
This is likely due to the modest level of weight loss achieved and the considerable overlap in 
weight loss between the intervention and control group, and consequent lack of power in the 
randomised analysis.  For example 23% of participants in the intervention arm and 19% of 
participants in the control gained more than 2.5kg 7. Secondly, when analysed as a single 
cohort, the improved statistical power resulting from our exploiting the variability from 
participant to participant in weight change as a continuous variable enabled detection of 
associations of changes in weight and waist with some biomarkers i.e. in triglycerides, leptin, 
liver function tests (ALT and GGT) and glycaemia and insulin metabolism (insulin, fasting 
glucose, 2 hour glucose and HOMA-IR). The models suggest that changes in weight would 
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need to be more substantial for changes in biomarkers become clinically significant. There 
was, interestingly, no evidence of a relationship between change in weight and/or change in 
waist on inflammatory markers, CRP and IL-6, nor on blood pressure. The effects of weight 
loss on cardiometabolic biomarkers have been observed in studies of other ethnic groups 15–
18, but not previously in South Asians.  These data provide novel information on magnitude 
of the dose-response relationship between change in weight (and waist) and change in 
biomarkers in this ethnic group, although we must be cautious in interpretation of statistically 
significant small effects in the context of multiple testing and non-randomised data.  
Nevertheless, the pattern of results are internally consistent in that leptin is a strong 
biomarker of fat mass and ALT and GGT are documented surrogate markers of liver fat in 
those who do not drink alcohol excessively 19.   
 
Non-alcoholic fatty liver disease (NAFLD) is an important clinical consequence of excess 
adiposity and can lead, in a minority of people, to more serious complications such as fibrosis 
and cirrhosis 19. One of the important observations from our model is that reductions in 
weight were associated with reductions in ALT and GGT (>2% reduction per kg weight lost).  
It is well-known that obesity, type 2 diabetes, and insulin resistance are closely linked to 
NAFLD 20 and lifestyle interventions such as weight loss and increased physical activity are 
associated with reductions in liver fat 21,22. The lack of association between change in weight 
and waist circumference and markers of inflammation (CRP and IL-6) in the longitudinal 
data is therefore unexpected. This may simply be an issue of lack of power and is in keeping 
with data from the Finnish Diabetes Prevention Study in people with IGT 23.    
 
Recent Mendelian randomisation analysis shows that the rs9939609 FTO single nucleotide 
polymorphism that is associated with small increases in BMI was associated with lower 
12 
 
HDL-cholesterol, higher insulin, higher 2-hour (but not fasting) glucose, higher liver 
enzymes (ALT and GGT), higher CRP (but not IL-6), higher triglycerides, and higher 
systolic and diastolic blood pressure 24. The present study extends these findings by showing 
the effect of moderate weight loss in a prospective study comprising weight loss and physical 
activity elements which will not only impact adiposity, but also muscle mass. Like the 
Mendelian randomisation study, we show that the effect of modest weight loss on 
cardiometabolic biomarkers is small, and patients must be encouraged to prevent weight gain 
or to maximise weight loss in order to yield tangible health benefits from reducing 
cardiometabolic risk factors.  It should also be noted that a Prevención con Dieta 
Mediterránea (PREDIMED) substudy suggested that diet quality (the Mediterranean diet) 
might beneficially influence cardiovascular risk factor biochemical parameters without 
specifically restricting calorie intake 25. Although the PODOSA complex intervention 
encouraged healthy eating, the specific effect of this component of the intervention could not 
be investigated. 
 
Strengths and weaknesses of the study require consideration. The first part of our study 
represents a randomised intervention trial, the gold standard for identifying causal 
mechanisms 26. As discussed above, the small size of the study and the limited effect of the 
intervention on adiposity make power an issue for the study.  Although use of prospective 
pooled data allows an analysis with greater power, we recognise that not all participants may 
have lost weight due to intentional weight change.  That noted, their motivation for trial 
inclusion was to lose weight so it is likely that most lost weight intentionally. The pooled data 
ignores the effect of 3 years of ageing on biomarkers of interest, focusing on the effect of 
changing weight over that time. It is important to acknowledge that our study is based on 
modelling a linear relationship between weight change and subsequent changes in 
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cardiometabolic biomarkers. Extrapolating these models to situations where there is more 
pronounced weight loss may not be valid; for instance, there may be proportionally increased 
benefit from losing larger amounts of weight via threshold effects. Indeed, we know from 
studies in mainly White European origin subjects with diabetes that 8kg weight loss can 
substantially alter liver fat levels and can reverse diabetes 27. How such weight loss can be 
achieved other than in highly motivated individuals is the topic of debate 28–30. We were not 
able to assess the effect of more pronounced weight loss on biomarkers due to limited power. 
There is some potential that changes in medication during follow-up may impact both weight 
and biomarkers of risk, but we did not have sufficient data to sensibly adjust for such effects, 
which are expected to be small, and the randomised design of the trial should limit baseline 
imbalances. 
 
In conclusion, the present study shows that a lifestyle intervention in South Asians with 
impaired fasting glucose or impaired glucose tolerance living in the UK which had only very 
moderate effects on adiposity did not improve biomarkers of cardiometabolic risk between 
study groups in a randomised comparison. Analysis as a single longitudinal cohort did, 
however, indicate that associations between adiposity changes and cardiometabolic 
biomarkers (specifically those related to total and ectopic fat mass and related glycaemia and 
insulin sensitivity) exist; decrease in weight was associated with favourable changes in 
markers in several domains of cardiometabolic risk. 
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Figure Legends 
Figure 1: Flow chart of participants who met inclusion/exclusion criteria for the study. 
 
 
Table 1 Baseline characteristics of study participants by randomised group 
 Characteristics at Baseline 
Characteristic Intervention group (n=75) Control group (n=76) 
Clinical/Demographic   
Male sex 33 (44%) 34 (45%) 
Age (years) 52.6 (10.3) 52.4 (9.8) 
Location 
Glasgow 
   Edinburgh 
 
59 (79%) 
16 (21%) 
 
59 (78%) 
17 (22%) 
Ethnic group 
 Indian 
 Pakistani 
 
26 (35%) 
49 (65%) 
 
24 (32%) 
52 (68%) 
Height (cm) 160.9 (10.6) 162.4 (8.0) 
Anthropometric   
Weight (kg) 79.2 (16.7) 80.5 (15.5) 
BMI (kg/m²) 30.5 (5.2) 30.5 (4.8) 
Waist circumference (cm) 102.2 (11.3) 103.2 (11.4) 
Lipids   
Total Cholesterol (mmol/L) 4.55 (0.84) 4.64 (0.95) 
HDL-c (mmol/L) 1.08 (0.31) 1.04 (0.27) 
Triglycerides (mmol/L) 1.50 (0.56) 1.64 (0.65) 
LDL-C (mmol/L) 3.17 (0.81) 3.27 (0.94) 
Liver function tests   
AST (U/L) 32.0 [25.8,39.8] 31.7 [22.8,40.1] 
ALT (U/L) 22.9 [16.5,31.4] 23.8 [15.3,30.8] 
GGT (U/L) 30 [19,41] 25 [19,41] 
Inflammatory/endothelial   
t-PA (ng/ml) 14.07 (7.46) 13.35 (6.41) 
CRP (mg/L) 2.82 [1.12,4.60] 3.45 [1.28,5.59] 
IL-6 (pg/ml) 1.15 [0.76,2.09] 1.28 [0.83,2.14] 
Metabolic   
Leptin (ng/ml) 27.2 [14.4,45.0] 33.9 [17.8,52.8] 
Insulin (µU/L) 13.6 [8.5,17.1] 15.1 [10.7,19.4] 
HOMA-IR  3.54 [2.24,4.58] 3.91 [2.59,5.12] 
Fasting plasma glucose (mmol/L) 5.80 (0.62) 5.81 (0.61) 
2 hour plasma glucose (mmol/L) 8.13 (1.65) 8.26 (1.52) 
Blood pressure   
Systolic blood pressure (mmHg) 137.5 (22.8) 137.5 (19.5) 
Diastolic blood pressure (mmHg) 82.3 (13.1) 83.91 (10.7) 
Continuous data are presented as means and standard deviations or medians and interquartile ranges; categorical 
data presented as numbers and percentages. 
 
Table 2 Relative change in active intervention versus control group (95% CI, p-values) in weight, waist circumference and biomarkers for the 151 participants with complete data  
Characteristic Absolute change  Effect estimate* (95% CI) p-value 
 Intervention group 
(3 year – baseline) 
Control group  
(3 year – baseline) 
Intervention vs Control 
(95% CI) 
  
Anthropometric      
Weight (kg) -1.14 (4.22) 0.30 (3.62) -1.44 (-2.71 to -0.18) -1.8% (-3.4%, -0.2%) 0.0256 
Waist circumference (cm) -2.22 (4.68) -0.63 (4.68) -1.59 (-3.09 to -0.08) -1.5% (-3.0%, -0.1%) 0.0390 
Lipids      
Total Cholesterol (mmol/L) 0.13 (0.83) 0.10 (0.80) 0.03 (-0.23 to 0.30) 0.7% (-5.0%, 6.6%) 0.7947 
HDL-c (mmol/L) 0.08 (0.20) 0.03 (0.14) 0.05 (0.00 to 0.11) 5.0% (-0.3%, 10.4%) 0.066 
Triglycerides (mmol/L) -0.04 (0.55) 0.08 (0.47) -0.12 (-0.28 to 0.04) -7.6% (-17.8%, 2.5%) 0.1501 
LDL-C (Friedewald) 0.05 (0.78) 0.05 (0.71) 0.01 (-0.23 to 0.24) 0.2% (-7.2%, 7.5%) 0.9667 
Liver function      
AST (µ/L) 1.90 [-9.10,12.10] -0.85 [-9.95,9.00] 1.22 (-5.05 to 8.77) 3.4% (-14.2%, 24.6%) 0.7220 
ALT (µ/L) 0.50 [-7.80,5.40] -3.60 [-10.80,2.45] 4.16 (-0.92 to 10.26) 16.0% (-3.5%, 39.6%) 0.1137 
GGT (µ/L) 0.00 [-9.00,3.00] -1.00 [-8.50,4.50] 4.21 (-3.36 to 13.17) 9.5% (-7.5%, 29.6%) 0.2917 
Inflammatory/endothelial      
t-PA (ng/ml) 0.94 (10.69) 0.50 (8.38) 0.45 (-2.64 to 3.53) 3.2% (-19.1%, 25.5%) 0.7765 
CRP (mg/L) 0.07 [-1.15,1.10] 0.12 [-1.81,1.36] 0.80 (-0.48 to 2.50) 18.1% (-10.9%, 56.6%) 0.2447 
IL-6 (pg/ml) -0.24 [-0.87,0.08] -0.24 [-0.81,0.28] 0.02 (-0.32 to 0.44) 1.3% (-17.3%, 24.1%) 0.8999 
Metabolic      
Leptin (ng/ml) -1.00 [-7.31,5.82] 2.57 [-2.93,9.69] -5.13 (-11.48 to 2.78) -13.7% (-30.8%, 7.5%) 0.1883 
Insulin (µm/L) 1.13 [-3.71,3.86] -0.07 [-4.09,4.20] 2.24 (-0.62 to 5.64) 14.3% (-4.0%, 36.1%) 0.1307 
HOMA-IR 0.29 [-0.84,1.41] -0.16 [-1.21,1.33] 0.58 (-0.23 to 1.57) 14.3% (-5.6%, 38.5%) 0.1694 
Fasting plasma glucose (mmol/L) 0.08 (0.68) 0.10 (0.91) -0.01 (-0.27 to 0.25) -0.2% (-4.7%, 4.3%) 0.9187 
2 hour plasma glucose (mmol/L) -0.69 (2.68) -0.30 (2.44) -0.40 (-1.22 to 0.43) -4.8% (-14.8%, 5.2%) 0.3447 
Blood pressure      
Systolic blood pressure (mmHg) 0.14 (16.94) 1.19 (18.21) -1.05 (-6.71 to 4.61) -0.8% (-4.9%, 3.4%) 0.7141 
Diastolic blood pressure (mmHg) -1.07 (10.87) -1.07 (10.84) 0.00 (-3.49 to 3.49) 0.0% (-4.2%, 4.2%) 0.9996 
*Estimates are the relative difference between the intervention and control groups. 
Absolute change data are presented as means and standard deviations or medians and interquartile ranges 
 
Table 3 Association between change in weight and change in biomarker 
 Per 1kg reduction in weight  
Characteristic Absolute Change 
(95% CI) 
Relative Change 
(95% CI) 
p-value 
Lipids    
Total Cholesterol (mmol/L) -0.03 (-0.06 to 0.00) -0.6% (-1.4% to 0.1%) 0.0787 
HDL-c (mmol/L) 0.00 (-0.01 to 0.01) 0.2% (-0.5% to 0.9%) 0.5034 
Triglycerides (mmol/L) -0.02 (-0.04 to 0.00) -1.3% (-2.6% to 0.0%) 0.0484 
LDL-C (mmol/L) -0.03 (-0.06 to 0.00) -0.9% (-1.8% to 0.1%) 0.0697 
Liver function    
AST (U/L) -0.14 (-0.98 to 0.68) -0.4% (-2.8% to 1.9%) 0.7246 
ALT (U/L) -0.64 (-1.21 to -0.05) -2.5% (-4.7% to -0.2%) 0.0323 
GGT (U/L) -0.97 (-1.87 to -0.04) -2.2% (-4.2% to -0.1%) 0.0397 
Inflammatory/endothelial    
t-PA (ng/ml) 0.17 (-0.21 to 0.56) 1.3% (-1.5% to 4.0%) 0.3772 
CRP (mg/L) -0.06 (-0.21 to 0.10) -1.4% (-4.8% to 2.2%) 0.4496 
IL-6 (pg/ml) 0.01 (-0.03 to 0.06) 0.6% (-1.9% to 3.3%) 0.6412 
Metabolic    
Leptin (ng/ml) -2.42 (-3.32 to -1.54) -6.5% (-8.9% to -4.1%) <0.0001 
Insulin (µU/L) -0.58 (-0.91 to -0.26) -3.7% (-5.8% to -1.7%) 0.0005 
Fasting plasma glucose (mmol/L) -0.04 (-0.08 to -0.01) -0.8% (-1.3% to -0.2%) 0.0071 
2 hour plasma glucose (mmol/L) -0.19 (-0.29 to -0.09) -2.3% (-3.5% to -1.1%) 0.0002 
HOMA-IR -0.18 (-0.27 to -0.09) -4.5% (-6.7% to -2.2%) 0.0002 
Blood pressure    
Systolic BP (mmHg) -0.41 (-1.12 to 0.29) -0.3% (-0.8% to 0.2%) 0.2506 
Diastolic BP (mmHg) -0.27 (-0.71 to 0.17) -0.3% (-0.9% to 0.2%) 0.2229 
 
Table 4 Association between change in waist circumference and change in biomarker 
 Per 1cm reduction in waist  
Characteristic Absolute Change 
(95% CI) 
Relative Change 
(95% CI) 
p-value 
Lipids    
Total Cholesterol -0.01 (-0.04 to 0.01) -0.3% (-0.9% to 0.3%) 0.3459 
HDL-c  0.00 (0.00 to 0.01) 0.2% (-0.4% to 0.8%) 0.4399 
Triglycerides  -0.02 (-0.04 to 0.00) -1.1% (-2.2% to 0.0%) 0.0483 
LDL-C  -0.01 (-0.04 to 0.01) -0.4% (-1.2% to 0.4%) 0.3445 
Liver function    
AST  -0.28 (-0.98 to 0.43) -0.8% (-2.8% to 1.2%) 0.4343 
ALT  -0.56 (-1.04 to -0.05) -2.2% (-4.0% to -0.2%) 0.0291 
GGT  -0.53 (-1.31 to 0.27) -1.2% (-3.0% to 0.6%) 0.1960 
Inflammatory/endothelial    
t-PA  0.15 (-0.17 to 0.48) 1.1% (-1.2% to 3.5%) 0.3487 
CRP  -0.06 (-0.19 to 0.07) -1.4% (-4.3% to 1.6%) 0.3544 
IL-6  -0.01 (-0.05 to 0.03) -0.4% (-2.5% to 1.8%) 0.7231 
Metabolic    
Leptin  -1.50 (-2.28 to -0.67) -4.0% (-6.1% to -1.8%) 0.0005 
Insulin  -0.37 (-0.64 to -0.09) -2.4% (-4.1% to -0.6%) 0.0105 
Fasting glucose -0.03 (-0.06 to -0.01) -0.6% (-1.0% to -0.1%) 0.0217 
2-hr glucose  -0.14 (-0.23 to -0.06) -1.7% (-2.8% to -0.7%) 0.0010 
HOMA-IR -0.12 (-0.19 to -0.04) -2.9% (-4.8% to -0.9%) 0.0045 
Blood pressure    
Systolic BP  -0.27 (-0.87 to 0.33) -0.2% (-0.6% to 0.2%) 0.3747 
Diastolic BP  -0.29 (-0.66 to 0.08) -0.3% (-0.8% to 0.1%) 0.1223 
 
